Perceptions of prevalence, consequences, and strategies for managing contraband substance use in an inpatient concurrent disorders program: A qualitative study of patient perspectives and survey of clinician perspectives.
concurrent disorders
contraband substance use
frontline staff perspectives
patient perspectives
patient substance use
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
04
2022
accepted:
15
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Inpatient treatment programs for substance use disorders (SUDs) typically have an abstinence policy for patients, but unsanctioned substance use nonetheless takes place and can have significant negative clinical impacts. The current study sought to understand this problem from a patient perspective and to develop strategies for improved contraband substance management in an inpatient concurrent disorders sample. First, a qualitative study ( Patients reported that contraband substance use was present and had significant negative consequences clinically. Recommendations from patients included more extensive urine drug screening, the use of drug-sniffing dogs, and direct contingencies for contraband use. Nineteen staff competed an anonymous follow-up questionnaire to evaluate the viability of these strategies, revealing variable perceptions of feasibility and effectiveness. These findings emphasize the adverse consequences of contraband substance use in addiction treatment programs and identify patient-preferred strategies for managing this challenge.
Identifiants
pubmed: 36147979
doi: 10.3389/fpsyt.2022.911552
pmc: PMC9485475
doi:
Types de publication
Journal Article
Langues
eng
Pagination
911552Informations de copyright
Copyright © 2022 Rahman, Raymond, Labuguen, Gladysz, Holshausen, Brasch, Amlung and MacKillop.
Déclaration de conflit d'intérêts
JM was a principal in BEAM Diagnostics, Inc., and a consultant to Clairvoyant Therapeutics, Inc., but neither role has any bearing or relevance to the reported research. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Drug Alcohol Rev. 2015 Sep;34(5):499-502
pubmed: 25944526
Eur Addict Res. 2006;12(2):96-101
pubmed: 16543745
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
PLoS One. 2020 Mar 5;15(3):e0229713
pubmed: 32134973
Schizophr Bull. 2012 Nov;38(6):1288-96
pubmed: 22516147
Prev Med. 2000 Aug;31(2 Pt 1):159-66
pubmed: 10938217
Harm Reduct J. 2009 Jul 29;6:19
pubmed: 19638238
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Drug Alcohol Depend. 2010 Jul 1;110(1-2):137-43
pubmed: 20347232
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Arch Intern Med. 2012 Nov 26;172(21):1670-4
pubmed: 23128676
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Pain Res Manag. 2015 Mar-Apr;20(2):84-8
pubmed: 25562839
Can J Psychiatry. 2008 Dec;53(12):800-9
pubmed: 19087478